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To the Editor, 
As of March 2020, the novel coronavirus disease 2019 (COVID-19) caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic. The novelty of the 
virus is the driving force for numerous clinical trials taking place in an attempt to discover 
appropriate therapeutic agents.1 Many pharmacological agents have shown promising results, 
including Clofazimine.2,3 More recently, a prospective open-label randomised controlled clinical 
trial of dual therapy with interferon beta-1b and Clofazimine for COVID-19 patients is being 
conducted.  
 
Clofazimine is licensed for use against mycobacterial infection and as an adjunct agent for the 
treatment of multibacillary leprosy. However, it has also proven to comprise immunosuppressive 
properties.2 Therefore, we would like to outline a potential use for Clofazimine in COVID-19 
infections, where it could be a potential prophylactic and therapeutic agent in the management of 
critically ill patients. 
 
The most important cause of mortality post-infection with COVID-19 is a cytokine storm leading 
to end organ damage from inflammation.2 Thus, one of the main therapeutic treatments being used 
to increase survival, reduce inflammatory sequelae and decrease hospitalization following 
COVID-19 pneumonia are anti-inflammatory drugs. Clofazimine is an antibiotic with anti-
inflammatory properties, which can potentially be used for the treatment of COVID-19.2,3 
 
In patients with severe infection leading to cytokine storm, the use of immunosuppressive agents 
has proven beneficial.2,3 Indeed, clofazimine can inhibit the proliferation and activation of T-
lymphocytes through inhibition of the sodium-potassium ATPase.3,4 This immunomodulatory 
effect of clofazimine has proven beneficial in the treatment of autoimmune disorders such as 
psoriasis and multiple sclerosis.4 Yuan et al., (2020) reported significant decrease in the mRNA 
expression of IL-6 (p=0.0001), TNF-α (p=0.0006), and CCR4 (p=0.0029) in the hamsters treated 
with clofazimine.2  
 
Interestingly, antiviral synergistic effects have been reported when Clofazimine is co-administered 
with Remdesivir.2 The co-application of clofazimine and remdesivir in an in-vitro cellular assay 
with a 10% concentration of fetal bovine serum resulted in a nearly 20-fold reduction in the 
concentrations of remdesivir required to inhibit viral replication by 90%. This synergistic 
pharmacological effect did not elicit detectable cytotoxic changes. However, to further narrow the 
in-vivo side effects profile, clofazimine can be administered via inhalation reducing its systemic 
side effects such as skin discoloration and gastrointestinal discomfort.5 
 
In summary, clofazimine with its anti-inflammatory and immunomodulatory effect with minimal 
side-effects could increase survival in critically ill patients infected with the COVID-19 virus.  
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